Inogen

Inogen, Inc. engages in the development, manufacture, and marketing of portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Its products include Inogen One G4 system, Inogen One G3 system, Inogen One G5 system, Inogen TAV, and Inogen at Home. The company was founded by Alison Perry, Alison K. Bauerlein, Brenton Taylor, and Byron Myers on November 27, 2001 and is headquartered in Goleta, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Inogen reports revenue growth amidst challenges, eyes positive EBITDA

Inogen reported revenue growth in Q4 2022 despite challenges and aims for positive adjusted EBITDA by Q4 2023. The company successfully managed supply chain challenges and plans new product launches in 2023.
While facing challenges in DTC evolution and gross margin decline, Inogen sees promising market opportunities for sustainable growth. The company's strategic decisions to secure supply assurance and focus on innovation position it for future success.
With a focus on addressing challenges, leveraging strengths, and capitalizing on opportunities, Inogen is poised for growth and profitability in 2023. The company's commitment to managing disruptions and driving commercial strategy reflects a positive outlook for the future.

Inogen reports Q1 performance meeting expectations, eyes profitability by Q4

Inogen's Q1 2023 performance was mixed, with revenue meeting expectations but facing challenges in certain sales segments.
The company's strategic focus on patient-centric models and product expansion positions it well for future growth.
With a clear roadmap to profitability by Q4 2023 and a strong financial position, Inogen remains optimistic about its outlook.

Inogen reports Q2 revenue shortfall, focuses on strategic growth

Inogen faced challenges in Q2 2023 but is focused on strategic initiatives to drive growth and regain lost business.
The company's financial results were impacted by supply chain constraints, aggressive pricing tactics, and restructuring charges.
Opportunities for growth exist through international expansion, product enhancements, and entering new market segments.
Management's emphasis on commercial execution and innovation highlights a commitment to sustainable growth.

Inogen reports Q3 revenue decline, eyes international growth opportunities

Inogen faced revenue declines in Q3 2023, driven by challenges in direct-to-consumer and domestic B2B sales.
Despite these setbacks, the company showed strength in international B2B and rental revenue growth.
Operational efficiency improvements and strategic cost controls are crucial for addressing margin pressures and financial performance.
The acquisition of Physio-Assist underscores Inogen's commitment to expanding its product portfolio and enhancing market competitiveness.

Inogen reports $316M full-year revenue, eyes growth amid challenges

Inogen's Q4 2023 earnings call highlighted achievements, challenges, and opportunities. The company aims to drive growth through strategic priorities, innovation, and market leadership. Despite facing challenges in revenue and net loss, Inogen is focused on improving performance and capitalizing on market opportunities.

Inogen reports solid Q1 earnings, eyes growth amid market challenges

Inogen's Q1 2024 performance reflects steady revenue growth, improved gross margins, and prudent cost management. The company's strategic priorities, strong financial position, and revenue guidance for Q2 2024 signal resilience and growth potential amidst market challenges and opportunities.

Inogen reports Q2 revenue growth and profitability amidst operational challenges

Inogen's Q2 2024 performance showed revenue growth, improved gross margin, and achieved adjusted EBITDA profitability.
While facing challenges like increased operating expenses and DTC sales decline, the company is focused on sustainable profitability.
Opportunities lie in channel-specific strategies, innovation pipeline expansion, and long-term growth investments.

Inogen reports $89M Q3 revenue with improved profitability and strategic growth

Inogen delivered solid Q3 performance with revenue growth and profitability. Faces challenges in direct-to-consumer sales and net loss. Opportunities lie in improving sales force efficiency and expanding market reach. Strong financial position for future growth initiatives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Inogen, Inc. is a medical technology company, which engages in the development, manufacture, and marketing of portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Its products include Inogen One G4 system, Inogen One G3 system, Inogen One G5 system, Inogen TAV, and Inogen at Home. The company was founded by Alison Perry, Alison K. Bauerlein, Brenton Taylor, and Byron Myers on November 27, 2001 and is headquartered in Goleta, CA.

Inogen (INGN) delivered earnings and revenue surprises of -36.36% and 0.02%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Inogen (INGN) Q4 Earnings Miss Estimates

Inogen, Inc. (INGN) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

Moving Average Crossover Alert: Inogen

Intelsat

United States Steel

Big declines in stock price may bring big opportunities for patient investors.

Wall Street Has Given Up on These 3 Stocks & That's a Huge Mistake

Inogen (INGN) expects direct-to-consumer sales to be its fastest-growing channel in 2020.

Inogen (INGN) Announces Preliminary Q4 Results, Slashes View

Inogen (INGN) reported earnings 30 days ago. What's next for the stock?

Inogen (INGN) Up 7.2% Since Last Earnings Report: Can It Continue?

Inogen: Solid Bet For End Of 2019

Softness in domestic and international business-to-business revenues impact Inogen's (INGN) Q3 results.

Inogen's (INGN) Q3 Earnings and Revenues Beat Estimates

Inogen, Inc. (INGN) CEO Scott Wilkinson on Q3 2019 Results - Earnings Call Transcript

Inogen (INGN) delivered earnings and revenue surprises of 34.78% and 0.42%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Inogen (INGN) Q3 Earnings and Revenues Top Estimates

Inogen is now trading at less than a fifth of its all-time high. The market has massively punished Inogen for what seems to be temporary headwinds.

Inogen: Hold Your Breath And Buy

Why Is Inogen (INGN) Down 5.9% Since Last Earnings Report?

Inogen has real operating challenges at hand, yet valuations become cheaper by the day.

Inogen: Investors Should Take A Breath

Inogen (INGN) gains from international revenues in Q2; slashes 2019 guidance.

Inogen (INGN) Q2 Earnings Miss Estimates, 2019 View Lowered

Inogen, Inc. (INGN) CEO Scott Wilkinson on Q2 2019 Results - Earnings Call Transcript

Shares sink after the medical-device maker reported weak second-quarter results and slashed guidance. Again.

Why Inogen Shareholders Are Having Another Tough Day

Inogen (INGN) delivered earnings and revenue surprises of -10.00% and -5.55%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Inogen (INGN) Misses Q2 Earnings and Revenue Estimates

AbbVie

Intercept Pharma

Find out which stocks have our team of healthcare experts feeling excited right now.

3 Top Healthcare Stocks to Buy in July

Madrigal Pharmaceuticals

The following securities are falling knives, meaning their share prices have declined more than 59% over the last 52 weeks.

2 Falling Knives With No Debt

Inogen (INGN) Down 6.8% Since Last Earnings Report: Can It Rebound?

Inogen has corrected sharply off its fall 2018 peak as small/mid-cap med-tech valuation premiums have fallen and growth expectations for the company have come down.

Can Reduced Expectations And A New Product Rebuild Inogen's Premium?

The stock sinks after the medical device marker slashes its full-year guidance.

Why Inogen Shares Are Plunging Today

Inogen (INGN) slashes revenue and net income guidance for 2019.

Inogen (INGN) Earnings Miss Estimates in Q1, View Lowered

Inogen, Inc. (INGN) CEO Scott Wilkinson on Q1 2019 Results - Earnings Call Transcript

Inogen Inc.  shares dropped in the extended session Tuesday after the maker of oxygen therapy systems missed Wall Street earnings targets and cut its outlook for the year.

Inogen stock drops 20% after earnings miss, cut outlook

Inogen's (INGN) first-quarter 2019 results are expected to get a boost from product launches.

News for Inogen Stock (INGN)